Immobilized Human CCR5 Full Length Protein-VLP (Cat. No. CC5-H52P3) at 2 μg/mL (100 μL/well) can bind Anti-Human CCR5 Antibody, Mouse IgG2a with a linear range of 2-78 ng/mL (QC tested). The mean peak Radius of VLP is 55-75 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

该平台生产的VLPs可溶，大小为100-300nm，可用于各种展示库筛选，以及免疫/ELISA/SPR/BLI/CAR-T阳性率检测，助力先导分子的发现。 目前已利用该平台生产出系列VLP全长多次跨膜蛋白，包括C5AR1、CXCR4、CCR5、CCR8、CD63、Claudin18.2、Cluadin6等多个热门靶点，且均经过活性验证。 多次跨膜蛋白（multipass membrane protein，MMP）是一类包含2个或多个跨膜结构域的蛋白，参与多种信号转导以响应细胞对外界的刺激，在维持细胞结构 …

2009年12月11日 · In this study, we compared the immune responses induced by VLP-based vaccines targeting macaque CCR5 upon intramuscular and pulmonary immunizations. Both routes of immunization resulted in high-titer antibody responses against the vaccine preparation, and anti-CCR5 antibodies were effective at blocking SIV infection.

CCR5 expression is regulated at three levels: (1) genetic factors (reviewed in Section 8); (2) factors involved in activation, signaling and trafficking of the receptor including desensitization (the receptor stops responding to stimulus), internalization (receptors are removed from the cell surface after stimulus and move to intracellular ...

Immobilized Recombinant Human CCR5 Protein (VLP, Flag & His-Strep Tag) (Cat: 13022-H82H) at 5 μg/mL (100 μL/well) can bind Leronlimab-Derived Anti-CCR5 Antibody, Human IgG1, the EC 50 is 10-30 ng/mL.

目前已利用该平台生产出系列VLP全长多次跨膜蛋白产品，包括C5AR1、CXCR4、CCR5、CCR8、CD63、Claudin18.2、Cluadin6等多个热门靶点，且均经过活性验证。 还可根据客户需求提供目标蛋白定制服务。

The current application uses virus-like particles as a support to present CCR5 peptide antigens. Objectives: The virus-like particle (VLP)-CCR5 composition aims to function as either a preventative and/or therapeutic vaccine inducing durable autoantibodies that can block CCR5 and prevent HIV entry or attenuate disease progression.

Immobilized Human CCR5 Full Length Protein-VLP (Cat. No. CC5-H52P3) at 2 μg/mL (100 μL/well) can bind Anti-Human CCR5 Antibody, Mouse IgG2a with a linear range of 2-78 ng/mL (QC tested).

2009年12月11日 · We have developed VLP-based vaccines that target two domains of the HIV coreceptor CCR5 that are involved in HIV binding. These vaccines induce anti-CCR5 antibodies that bind to native CCR5 and inhibit SIV infection in vitro .

The C-C chemokine receptor type 5 (CCR5) is a key player in HIV infection due to its major involvement in the infection process. Investigations into the role of the CCR5 coreceptor first focused on its binding to the virus and the molecular ...